NBS-101: Phase II started

OLGX began a dose-ranging Phase II trial in 275 osteoporosis patients in the U.K. and Denmark. The trial has 5 arms, 4 of which are double-blind with doses of 750 mg, 1,000 mg and 2,000 mg of once-dai...